Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05178862
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇧🇪Saint Luc University Hospital, Brussels, Belgium
A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT05140096
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT05076409
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT05074602
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 60
- Registration Number
- NCT05059145
- Locations
- 🇸🇪
Danderyd Hospital, Dep. of Obstetrics and Gynecology, Stockholm, Sweden
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04933682
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT04871724
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 29
- Registration Number
- NCT04702464
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 252
- Registration Number
- NCT04626258
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04551963
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺John Flynn Private Hospital, Tugun, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.